Safety of Tocilizumab on Rheumatoid Arthritis in Patients with Interstitial Lung Disease
Open Access Rheumatology: Research and Reviews · 2024-06 · Volume 16 · 127-135
DOI: 10.2147/oarrr.s462662 ↗Kurz gefasst
Fachartikel in der Zeitschrift Open Access Rheumatology: Research and Reviews, 2024-06. Verfasst von Naotatsu Otsuji und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine and Clinical Immunology, Dokkyo Medical University Saitama Medical Center, Koshigaya, Saitama, Japan. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Respiratory Medicine and Clinical Immunology, Dokkyo Medical University Saitama Medical Center, Koshigaya, Saitama, Japan.
- National Hospital Organization Utsunomiya Hospital, Utsunomiya, Tochigi, Japan.
ORCID-Profile: Kumiya Sugiyama, Hirokuni Hirata
Zitieren
APA
Otsuji, N., Sugiyama, K., Owada, T., Arifuku, H., Koyama, K., Hirata, H., & Fukushima, Y. (2024). Safety of Tocilizumab on Rheumatoid Arthritis in Patients with Interstitial Lung Disease. Open Access Rheumatology: Research and Reviews, Volume 16, 127-135. https://doi.org/10.2147/oarrr.s462662
Vancouver
Otsuji N, Sugiyama K, Owada T, Arifuku H, Koyama K, Hirata H, et al. Safety of Tocilizumab on Rheumatoid Arthritis in Patients with Interstitial Lung Disease. Open Access Rheumatology: Research and Reviews. 2024;Volume 16:127-135. doi:10.2147/oarrr.s462662
BibTeX
@article{Otsuji2024,
author = {Otsuji, Naotatsu and Sugiyama, Kumiya and Owada, Takayoshi and Arifuku, Hajime and Koyama, Kenya and Hirata, Hirokuni and Fukushima, Yasutsugu},
title = {Safety of Tocilizumab on Rheumatoid Arthritis in Patients with Interstitial Lung Disease},
journal = {Open Access Rheumatology: Research and Reviews},
year = {2024},
volume = {Volume 16},
pages = {127--135},
doi = {10.2147/oarrr.s462662}
}
EUVIMED